Evaluation of the male reproductive organs after treatment with continuous sustained delivery of statin for fracture healing.
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used for the treatment of hyperlipidemia, and recent in vitro and animal data suggest that statins promote bone formation and increase bone strength. We examined the relationship between sustained continuous delivery of statin and fracture healing rates in adult male animals with femoral segmental fractures. Because statin affects the production of cholesterol we also evaluated the influence of statin, on adrenal and testicular steroidogenesis and the morphology of the reproductive tract tissues in animals receiving statin for a period of 12 weeks post surgery. Simvastatin significantly increased fracture healing and without significant influence on the body weights and the weights of the reproductive organs. Basal plasma LH, FSH and testosterone levels were not affected by active treatment with simvastatin. Reproductive tissue morphology was unchanged by local sustained release of statin. In conclusion, long-term simvastatin treatment delivered at a fracture target site did not influence testicular reproductive and endocrine function, but was able to effectively heal complicated segmental fracture.
Adah
Felix
F
University of Mississippi Medical Center, Jackson, MS, USA.
Benghuzzi
Hamed
H
Tucci
Michelle
M
Russell
George
G
Tsao
Audrey
A
Olivier
Jake
J
England
Barry
B
D000818:Animals; D002784:Cholesterol / Q000097:blood; D003692:Delayed-Action Preparations / Q000008:administration & dosage*; D005264:Femoral Fractures / Q000188:drug therapy* / Q000473:pathology*; D017102:Fracture Healing / Q000187:drug effects*; D005837:Genitalia, Male / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology*; D042341:Gonadal Hormones / Q000097:blood; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D019821:Simvastatin / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D042341:Gonadal Hormones; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol; D019821:Simvastatin